Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Anti-SARS-CoV-1 and −2 nanobody engineering towards avidity-inspired therapeutics

Eugene M. Obeng\textsuperscript{a,b,⁎}, Christian K.O. Dzuvor\textsuperscript{b}, Michael K. Danquah\textsuperscript{c,⁎⁎}

\textsuperscript{a} Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia
\textsuperscript{b} Bioengineering Laboratory, Department of Chemical and Biological Engineering, Monash University, Clayton, VIC 3800, Australia
\textsuperscript{c} Department of Chemical Engineering, University of Tennessee, Chattanooga 615 McCallie Ave, Chattanooga, TN 37403, United States

ABSTRACT

In the past two decades, the emergence of coronavirus diseases has been dire distress on both continental and global fronts and has resulted in the search for potent treatment strategies. One crucial challenge in this search is the recurrent mutations in the causative virus spike protein, which lead to viral escape issues. Among the current promising therapeutic discoveries is the use of nanobodies and nanobody-like molecules. While these nanobodies have demonstrated high-affinity interaction with the virus, the unpredictable spike mutations have warranted the need for avidity-inspired therapeutics of potent inhibitors such as nanobodies. This article discusses novel approaches for the design of anti-SARS-CoV-1 and −2 nanobodies to facilitate advanced innovations in treatment technologies. It further discusses molecular interactions and suggests multivalent protein nanotechnology and chemistry approaches to translate mere molecular affinity into avidity.

© 2021 Elsevier Ltd. All rights reserved.

Keywords: Coronavirus Nanobody Affinity Avidity Multivancy Nanoparticles Therapy

Contents

Introduction ...................................................................................................................... 2
Coronavirus disease: an overview of components, functions and mechanism of infection .................................................. 2
Spike glycoprotein: the molecular and structural similarities and differences ............................................................... 3
Nanobodies: molecular and structural characteristics .................................................................................................. 4
Nanobody interaction with coronavirus spike .............................................................................................................. 5
Avidity-inspired approaches for effective viral blocking ............................................................................................... 5
Protein engineering approaches ................................................................................................................................. 5
Immunoglobulin (Ig) Fc fusion approach .................................................................................................................... 5
Nanobody cocktail approach ...................................................................................................................................... 7
Engineered linker fusion approach .................................................................................................................................. 7
Multimeric domains and non-immunoglobulin scaffolds .............................................................................................. 7
Protein cages and virus-like particles ........................................................................................................................... 8
Particulate nanotechnology approaches .................................................................................................................. 10
Avidity-inspired nanobody therapeutics: outlook ........................................................................................................ 11
Conclusion ................................................................................................................................................................. 11
CRedit authorship contribution statement ................................................................................................................... 11

⁎ Corresponding author.
⁎⁎ Corresponding author.
E-mail addresses: eugene.obeng@monash.edu (E.M. Obeng), michael-danquah@utc.edu (M.K. Danquah).

https://doi.org/10.1016/j.nantod.2021.101350
1748-0132/© 2021 Elsevier Ltd. All rights reserved.
Introduction

The past two decades have witnessed the emergence of many deadly coronavirus-associated (CoV) diseases on both epi- and pandemic levels in forms such as severe acute respiratory syndrome (SARS) and the middle east respiratory syndrome (MERS). The disease, especially in the present decade, has warranted the search for potent antidotes such as vaccines [1–3] and therapeutics [4–6] to help combat the seemingly unending life loss. Antibodies and soluble angiotensin-converting enzyme 2 (ACE2)- the virus receptor on the cell- are the most popular biologics suggested for coronavirus treatment. Also, several nanobodies have been reported as potent inhibitors of coronavirus and present advantages in terms of size, solubility and stability. However, with the emergence of mutated virus strains capable of escaping inhibition by many monovalent blockers [7], it is presently highly expedient to probe into the design of potential inhibitors towards creating “avidity-inspired” therapeutics. We define an avidity-inspired therapeutic as one generated via the utilization of multivalent protein engineering and nano-technology approaches that translate mere molecular affinity into avidity of functional interactions for optimum cumulative performance.

This article provides a general overview of coronaviruses, emphasizing SARS-CoV-1 and −2 and their spike glycoproteins. The article follows to discuss nanobodies and their molecular architecture, highlighting key benefits. It henceforward presents the impressive nanobodies developed against the spike glycoprotein to date and suggests interesting multivalent approaches based on protein engineering and particulate nanochemistry to guide the development of treatment technologies against the challenges of spike mutations.

Coronavirus disease: an overview of components, functions and mechanism of infection

Coronavirus is a positive-strand RNA virus bound with a well-defined envelope. The virus belongs to the Coronaviridae family and is sub-classified into four genera: α-, β-, γ-, and δ-coronavirus [8]. The α- and β-coronaviruses appreciably infect mammals, whereas the γ- and δ-coronaviruses infect birds, fish and, at times, mammals. SARS-CoV-1 and −2 are β-coronaviruses and, thus, share similar structural and molecular architecture. As depicted in Fig. 1A, the β-coronaviruses possess protruding spike proteins that serve for receptor attachment and fusion to membranes. Their membrane glycoproteins shape the virion and support the nucleocapsid, whereas the envelope protein functions in viral assembly, release and pathogenesis [9, 10]. As expected, the viral genomic RNA harbours the replicative identity of the virus, whereas the nucleocapsid encapsidates the genome into the virus [9, 10]. During infection (Fig. 1B), the spike protein interacts with the cell-surface ACE2 receptor and fuses with the cell membrane with the assistance of host cell proteases such as cathepsin L and TMPRSS2.

Interestingly, the host invasion and virus propagation cycle would putatively be inefficient without the spike protein. Consequently, cell entry is preceded by viral RNA release, where the host transcription and translation machinery produce all components required for viral

![Fig. 1. Schematic description of β-coronaviruses (A) and their simplified cell entry and replication mechanism. Before cell invasion, the spike protein interacts with the ACE2 cell surface receptor (1) and fuses the cell membrane aided by enzymatic proteolysis (2). Next, the virus enters the cytosol and releases the positive-strand RNA (3), which adopts the host cell replicating and translation machinery (4) to propagate and package the virus (5). Finally, the matured virus exits through the exocytic pathway (6).](https://example.com/figure1.png)
replication and packaging. The packaged virus then plies the exocytic pathway out of the cell to infect other healthy cells to continue the cycle.

**Spike glycoprotein: the molecular and structural similarities and differences**

The critical role of the spike (S) glycoprotein in the virus’s life cycle is important for vaccine and therapy development, especially by understanding its molecular and structural characteristics. In general, the SARS-CoV-1 and −2 S glycoproteins are multidomain proteins consisting of 1255aa and 1273aa, respectively (Fig. 2A). The multidomain structure comprises a signal peptide (SP) and S1 and S2 sub-units from the N-terminus, respectively. In the native state, the structure forms a homotrimer. The S1 subunit harbours a rigid N-terminal domain (NTD) and a receptor-binding domain (RBD), responsible for receptor attachment. On the other hand, the S2 subunit is known for host cell membrane fusion and thus comprises a fusion peptide (FP), heptad repeat 1&2 (HR1&2), connecting domain (CD), transmembrane (TM) and cytoplasmic (CP) domains. One key distinguishing feature in SARS-CoV-2-S is the presence of multiple protease cleavage sites (S1/S2, S') located at the junction of the S1 and S2 sub-units. Unlike the S1 cleavage site processible by cathepsin and TMPRSS2, the S1/S2 site has expanded proteolytic activation machinery, including Furin-like proteases [11,12]. The protease expansion is putatively liable for the stability and transmission of SARS-CoV-2.

Notably, the spike proteins of SARS-CoV-1 and −2 exhibit differences in glycosylation levels (Fig. 2B). These glycans are host-derived and putatively play a role in protein folding, viral tropism and immune escape [13,14]. SARS-CoV-1-S has 23 N-acetylgalactosamines (NAGs) per protomer vis-a-vis 22 NAGs per protomer for SARS-CoV-2-S [15,16]. In SARS-CoV-2-S, 20 out of 22 glycans are conserved and distributed across both S1 sub-unit (i.e., 9 out of 13 NAGs conserved) and S2 sub-unit (all the 9 NAGs conserved) [16,17]. Thus, the presence of the glycans has the penchant for causing specific epitope shielding that may weaken the neutralization abilities of potential blockers and cause viral immune escape.

Notwithstanding, viral immune escape could also be caused by epitope-associated residue substitutions, deletions and insertions that lead to an altered epitope conformation, increased receptor binding affinity and overall antigenicity [18–21]. The concept of immune escape [22] and mutations of SARS-CoV-2 [23] have been excellently reviewed in recent papers for readers reference. Focusing on the RBDs, both SARS-CoV-1 and −2 SRBDs compose of five-stranded anti-parallel β-sheets (β1–β4 and β7) core that is linked together by short connecting α-helices and stabilized by three pairs of disulfide bonds [9,24,25]. This RBD structure lies the receptor-binding motif (RBM) positioned between β4 and β7. The RBM comprises a pair of β-strands (i.e., β5 and β6) and α-helices (i.e., α4 and α5) stabilized by a single disulfide bond at the distal end [24,25]. Interestingly, the RBD contains most of the receptor contacting residues and is thus essential for vaccine and therapy development. There are about 16 and 17 receptors contacting residues in SARS-CoV-1-S and SARS-CoV-2-S, respectively [24]. Fourteen of the contacting residues share similarities. The entire individual contacting residues interact with 20 ACE2 residues, where 17 of the ACE2 contact points are similar for SARS-CoV-1 and −2 [24]. Fig. 2C describes the β-sheets, α-helices and disulfide bond connections in SARS-CoV-2 RBD.
In terms of conformation dynamics, both RBDs show similar changes, as represented in Fig. 2D. For instance, they assume an up promoter (receptor accessible; metastable) and down promoter (receptor inaccessible; stable) states in the similitude of a hinge [15–17,26]. However, the conformation of SARS-CoV-1 SRBD packs tightly against the N-terminal domain of the neighbouring promotor, whereas SARS-CoV-2 SRBD angles closer to the central cavity of the trimer [16]. To this end, the cryptic characteristics of the spike protein open up interest in nanobody therapy due to its ability to target cryptic epitopes and viral canyons.

**Nanobodies: molecular and structural characteristics**

Nanobodies are single-domain, antigen-specific fragments derived from the heavy-chain-only antibodies (HCabs) of camelds, such as alpacas, llamas and dromedaries. These heavy-chain-only antibodies are a unique class of antigen binders serendipitously discovered during the retrieval of a single-chain variable fragment (scFv) from naive immunoglobulin (IgG) libraries [27]. Unlike canonical antibodies, which are heterotetrameric, the structure of HCabs is homodimeric and consists of two heavy chains fused to the constant fragment lacking the first constant domain (CH1) [37–38]. Importantly, the intrinsic hydrophilicity in nanobodies facilitates their facile production, especially in forms such as multimers to confer functionalities with the help of their hypervariable complementary determining regions (CDR1–3) encoded by the IGHV gene or generated via V-D-J gene recombination [30]. Both nanobodies and IgG V\textsubscript{H} have four framework structures (framework regions, FRs) which enclose the CDRs (Fig. 3C). Clearly, there is a high sequence resemblance between the human/mouse V\textsubscript{H} and cameld V\textsubscript{HH} generated for the same antigen. However, there is a pronounced presence of solvent-exposed, hydrophilic amino acid units in the FR2 of nanobodies (F42, E49, R50, and G52) which contrast with the hydrophobic residues of human V\textsubscript{H} (V42, G49, L50, and W52). This sequence variation does not cause any conformational alterations of the backbone [31]; nevertheless, the hydrophilic inclusions make nanobodies highly water-soluble [32,33]. On the other hand, antibody V\textsubscript{H} often suffers aggregation tendencies and stickiness [34–36]; its associated scFv versions are no different since they inherit the intrinsic properties of corresponding V\textsubscript{H}–V\textsubscript{L} domains [37,38]. Importantly, the intrinsic hydrophilicity in nanobodies facilitates their facile production, especially in forms such as multimers to confer avidity (see subsequent discussions). As such, several groups have incorporated the hydrophilic residues of nanobodies into IgG V\textsubscript{H} with resounding outcomes [39–41].

In terms of the CDR architecture, antibody V\textsubscript{H} has short-looped CDRs, whereas nanobodies (especially CDR1 and CDR3) are known to be flexibly extended such that they are capable of accessing catalytic sites of enzymes and cryptic epitopes such as viral surface canyons [42–45]. In nanobodies, the CDR1 and CDR3 are often linked by an interloop disulfide bond through Cys23 and Cys94, respectively.
This interloop disulfide bond is conserved among all nanobodies, and it serves a dual purpose of stabilizing the overall nanobody structure and rigidifying the base of the flexible CDR3 loop to facilitate a stronger epitope interaction [47]. The presence of the disulfide bond could also be the rationale for the thermal and chemical stability of nanobodies, and its removal does not significantly compromise the stability [48]. It is worth noting that dromedary-derived nanobodies sometimes have an additional stabilizing disulfide bond linking the CDR2 and CDR3 in a solvent-exposed fashion to prevent aggregation [47,49]. Fig. 3D shows the arrangement of the CDR loops within the nine β-stranded core architecture of a typical nanobody. The presence of the β-hairpin within the CDR3 contributes to the totemic cryptic epitope meandering.

In production terms, initial approaches for raising nanobodies shared similarity with the laborious conventional techniques for antibodies [50]. The method required the immunization of the camel with an immunogen of interest followed by blood lymphocyte isolation and mRNA extraction for cloning and gene library construction. Positive clones were selected via panning or immunos assay techniques prior to the final soluble nanobody expression. But the expression of nanobodies from this stage has been relatively straightforward, unlike the stringent methods for antibody production, which often suffer from batch-to-batch variability, instability, specificity, and selectivity. Interestingly, recent advancements in nanobody technology have seen an immense transformation aided by high-throughput sequencing, in silico translation and LC-MS/MS techniques to expedite nanobody identification and production [51,52]. These have resulted in a robust pipeline facile production of nanobodies in systems such as high-order eukaryotic cells [53–55], yeast [53–56], Escherichia coli [57] and Aspergillus [58]. These achievements put nanobodies in a position of commercial relevance for all ailments, including coronavirus disease. Lastly, nanobodies’ smaller size and stability characteristics offer high tissue penetrability advantages and allow the delivery of nanobody therapeutics through alternative routes (e.g., pulmonary via nebulization), which is hardly achievable by other products [44,56].

Nanobody interaction with coronavirus spike

The interaction of nanobodies with the coronavirus spike protein could be classified into three main groups: receptor binding site (RBS), non-receptor binding site (nRBS), and the overlapping cahoot interactions. For the RBS category, the nanobody competitively binds to the ACE2 receptor-associated epitope on the spike RBD to premature ly trigger the fusion machinery in the absence of ACE2. The result of this decoy interaction may not alter the RBD architecture but leads to the abrogation of cell membrane fusion and virus entry. On the other hand, the nRBS class interacts with the other sections of the spike protein to distort the spike protein’s conformational liberty and thus render it defective towards cell membrane interaction. Finally, the overlapping cahoot sits between RBS and nRBS, where the nanobody-spike protein interaction occurs at the boundary between the two previous scenarios discussed. In this case, the effect is a combination of blocking and distortion of conformation liberty.

In terms of nanobodies, Wrapp et al. [62] engineered a bivalent form of VHH-72 via fusion to the human IgG Fc domain. Compared to the monovalent state, the bivalent VHH-72 firmly bound SARS-CoV-2 RBD and neutralized SARS-CoV-2 pseudoviruses with a half-maximal inhibitory concentration (IC50) of approximately 13 nM. In the quest to boost the reported potency, the authors further modified VHH-72-Fc using computational modelling in a subsequent study [73]. Herein, the affinity-matured modified molecule
(V_{HH}72_S56A-Fc) neutralized SARS-CoV-1 and −2 at the sub-nanomolar level. Interestingly, the new design bound other serbacovirus clades and strongly prevented both SARS-CoV-2 wild type and virulent mutant variants in hamsters.

In another study involving llama and nanomice, Xu et al. [74] reported two groups of interesting nanobodies: Group 1 and 2. The Group 1 versions bound highly conserved epitopes within Serbacoviruses that are inaccessible to conventional antibodies. Also, the nanobodies bypass the antigenic drift associated with the spike variant E484K and N501Y. The Group 2 versions were strictly ACE2 inhibitors. However, they fail to neutralize SARS-CoV-2 variants bearing E484K or N501Y mutations within the ACE2-binding site of the spike RBD. Nevertheless, the Group 2 nanobodies elicited remarkable neutralization activity against these variants in their homotrimer-IgG Fc fusion state and showed an IC_{50} of 4–538 pM. This enhanced neutralization prowess is a result of enhanced avidity and concomitant crosslinking of multiple viral spike proteins. Also, Dong et al. engineered several humanized nanobody-Fc fusions based on isolated llama-derived nanobodies that prevent ACE2-RBD [75,76]. Among the versions ranging from monoclonal V_{HH}-Fc to tri-specific V_{HH}-Fc, the tri-specific version showed significantly better blocking and neutralization of SARS-CoV-2 pseudoviruses than the others. Similar concepts were published by other groups [77,78], where the multivalent nanobody-Fc fusions showed affinities (K_D) and IC_{50} ranging from 59.2 to 250 pM and 43–111pM, respectively. There is also the possibility to tether both ends of the Fc domain with nanobodies via engineered linkers to circumvent notorious incorrect pairing problems that may arise with direct bi or tri-specific nanobody-Fc.

On a different dimension, polyvalent immunoglobulins Fc of IgA and IgM could also be employed in ‘avidifying’ nanobodies since they, respectively, form dimers and pentamers in the presence of the joining chain (J-chain). For instance, the IgA-Fc approach was utilized for engineering ACE2 decoy receptors, where the ACE2-IgAFc neutralized both wild type and mutated variants (N501Y, L452R; N501Y and E484K) [79]. Also, Xu et al. [80] engineered SARS-CoV-2 IgA and IgM by stitching previously identified SARS-CoV-2 IgG1 monoclonal
antibodies onto IgA-Fc and IgM-Fc scaffold, respectively. Both engineered IgA and IgM strongly inhibited live SARS-CoV-2 virus better than their IgG-based counterparts. In particular, the work reported IgM-14 as the most potent neutralizer, where the enhanced avidity effect successfully neutralized the South African B.1.351, Brazilian P1 and UK B.1.17 variants by 374-, 547- and 45-fold, respectively, in comparison with their IgG counterparts. Furthermore, IgM-14 neutralized other resistant viruses and 21 generated RBD mutants, of which numerous reported antibodies fail to recognize. To even make smaller pentameric versions, research can consider using the 18-amino acid secretory tailpiece of the IgM to scaffold nanobodies in a similar fashion done in other areas [69,81–86].

**Nanobody cocktail approach**

The use of protein cocktails presents a promising avidity approach to thwart SARS-CoV-2 mutational escape, as demonstrated for antibodies [87–89]. In this case, the concocted antibodies achieve the optimum neutralization benefit if they bind to distinct and non-overlapping epitopes. Also, this approach offers conformational freedom to the blocking molecule, which may be advantageous. Given the promising features of nanobodies against the variants of concern, a combinatorial mixture of multiple non-overlapping nanobodies could offer superior protection in the fight against mutational escape. For instance, Pymm et al. [80] showed that a pairwise combination of four non-competing alpaca-derived nanobodies or their Fc-fusion versions potently neutralize wild-type SARS-CoV-2 and variants with N501Y and D614G mutation. The researchers reported a 104-fold reduction in the viral load of these strains in mice studies. Similarly, Dong et al. [75,76] showed in-silico pairwise combinations that their llama-derived nanobodies synergistically block SARS-CoV-2.

In another study that raised llama-derived nanobodies against individual spike protein subunits such S1, S2, and non-RBD [65], the researchers demonstrated the effect of cooperativity and synergism in cocktail therapies. Herein, the work identified nanobodies 71, 16 and 26 having high-affinity interaction \(K_D < 1\text{ nM}\) with S1 RBD, S1 non-RBD region, and S2 SARS-CoV-2, respectively. Furthermore, a pairwise binary combination of these nanobodies successfully blocked escape mutants and variants of concern. These results confirmed that careful selection of non-competing nanobodies is a plausible way to combat future SARS-CoV-2 recalcitrance.

**Engineered linker fusion approach**

Immunoglobulin-based fusion may not be devoid of aggregation due to woolly pairing of intra- and inter-chain disulphide bonds. Also, methods to quantitatively identify potentcocktails may be exponentially laborious, requiring a sophisticated multi-dimensional synergy framework, modelling and in-silico design to achieve batch-dependent dosage estimations. Moreover, the inclusion of cocktails components targeting the same epitope may deceptively display additive effects instead of an expected synergized low-concentration benefits. However, the use of engineered linker fusions obviates these challenges and presents extra advantages in relation to molecular proximity, especially when epitopes within the same spike protein are to be targeted. Moreover, strategic linking of nanobodies into bivalent, trivalent, bispecific and tri-specific formats becomes straightforward towards avidity-inspired therapies. With knowledge of intra-epitope distances on SARS-CoV-2 spike protein [91] and rational linker length engineering [92], the much-needed avidity-inspired nanobodies can be engineered to crosslink spike proteins in the prevention of immunity escape. For example, Colton et al. [93] assembled synthetic non-overlapping SARS-CoV-2 nanobodies into bi-paratopic and multivalent formats with linkers and reported approximately 600- and 1400-fold increase in spike protein binding affinity and virus neutralization potency, respectively. Herein, the most potent trivalent nanobody neutralized live SARS-CoV-2 virus with an IC\(_{50}\) of 4 nM. Koenig et al. [60] also engineered linker based multivalent and bi-paratopic nanobodies from the four individual nanobodies already mentioned. The engineered multivalent nanobodies displayed high avidity towards the spike protein and were 100-fold more potent than their monomeric nanobodies in neutralizing the SARS-CoV-2 virus. Impressively, biparatopic nanobody fusion (EV and VE) prevented escape mutant compared to binary nanobody cocktails E + U, E + V and E + W. Also, Xiang et al. [64] isolated ultrapotent anti-SARS-CoV-2 nanobodies with pico- to femtomolar affinities to SARS-CoV-2-S and inhibited live the SARS-CoV-2 virus at sub-nanogram per millilitre concentration. The researchers further engineered linker-based homo-, heterodimeric and homotrimeric nanobodies out of Nb20 and Nb21, using flexible linkers such as \((G5)_{25}\) and \((EK)_{31}\). The resulting multivalent nanobodies showed exceptional avidity and ultrahigh neutralization potency against SARS-CoV-2 virus. The authors showed in a subsequent report that their homotrimeric Nb21 (PIN-21) require low-dosage (0.2–0.6 mg/kg) to protected infected Syrian hamster [94]. Many other recent studies have demonstrated and confirmed the potential of linker-based bi-paratopic or multi-paratopic nanobodies for enhanced blocking and neutralization of SARS-CoV-2 variants [63,95–97].

Of note, the success of this approach indispensably dwells on impressive linker design and engineering techniques. As such, the nature, design and functionality of selected linkers contribute to the conformational freedom, expression yield, stability, bioactivity and pharmacokinetic profiles of the recombinant fusion protein [98,99]. Furthermore, the length and composition of the linker could also affect the cytotoxicity of the fusion protein [99]. Over the years, selection considerations include flexible, rigid, and in vivo cleavable linkers depending on the intended application. However, flexible glycine-serine rich linkers are the most preferred options for antibody fragments engineering to date. Readers are referred to Rosmalen et al. [100] and Gräwe et al. [92] for guidance in rational flexible linker design approaches in relation to multidomain protein engineering.

**Multimeric domains and non-immunoglobulin scaffolds**

So far, it is apparent that avid spike protein binding and viral blocking are enhanced as oligomeric assemblies and valency of nanobodies increase. In line with this, protein engineers have access to several beneficial higher oligomerization domains that could confer nanobodies with high-avidity abilities for SARS-CoV-2 treatment and mutational escape prevention. In addition, some of these scaffolds also allow steric complementary binding in the correct orientation for diverse complexities, passing on much-needed stability and protease cleavage resistance to involving molecules. Notably, stability and protease cleavage resistance are important for drug delivery purposes. Interestingly, some of these oligomeric domains have been utilized for multivalent antibodies engineering in other therapeutic applications as reviewed elsewhere [70,71]. However, despite these enormous efforts in searching for ultrapotent multivalent nanobodies against the SARS-CoV-2 virus, these oligomeric domains are yet to be utilized. Below are some straightforward oligomeric domain technologies capable of improving the valency of nanobodies from 2 through to 10.

For instance, helix-turn-helix motif leucine zipper dimerization peptide domains (Fos or Jun) can be used to generate mono-, bispecific, bivalent and tetravalent nanobodies imitating the Y-shape of antibodies [101]. Also, trivalent nanobodies can be generated by fusing a single nanobody to the N-terminal of trimeric domains such as foldon [102], triple-helical bundle, [103] viral capsid protein SHP [104], and collagen XV, VIII or triplex-forming peptide [105–107]. These resulting multivalent nanobodies could potentially bind and lock the trimeric spike protein to render the virus defective. For tetramerization, mono or bivalent nanobodies can be genetically fused to p53 protein TD [108], GCN4 amphipathic coiled-coil helix
and streptavidin core [110]. Moreover, biparatopic hexavalent nanobodies can be generated by fusing nanobodies to both exposed N- and C-terminus of trimeric TIE collagen domain [111]. Furthermore, pentameric nanobodies can be generated via fusion to the N-terminus of non-toxic verotoxin B-subunit [112]. Fusion to both the N- and C- terminus results in bivalent decameric molecules [113]. Lastly, heptavalent nanobodies can be exploited by N-terminus fusion with heptameric ring-like protein IMX313 [114] and heptameric domain of Archaeal RNA binding protein Sm1 [115]. Besides these interesting possibilities, we anticipate that a higher-order expression system such as yeast may be required to overcome potential challenges such as incorrect domain swapping, stoichiometry mismatch and aggregation problems.

Docking ligands also offer a flexible, alternative avenue to create multimeric proteins. For instance, SnoopTagr-DogTag [116], SpyTag-SpyCatcher [117], barnase–barstar [118] and dock-and-lock (DNL) assembly approach [119] can be exploited to design bivalent, trivalent and multi-specific tetravalent anti-SARS-CoV nanobody candidates with permanent, stable and robust pairing/association. However, in all these examples, the immunogenicity and overall safety are yet to be accessed appropriately. We, therefore, refer readers to Löfblom et al. [120] for more information on non-immunogenic scaffolds.

**Protein cages and virus-like particles**

Protein cages, viral-like particles (VLPs) and protein nanoparticle scaffolds serve as ideal platforms for multimerizing protein molecules. This attribute stems from their interesting properties, including optimal size and space orientation, tunable surface area and valency, biocompatibility and stability, monodispersity, and many others [121,122]. These hallmarks make it interesting to attempt their use for avidity-inspired nanobodies therapeutics. Another hallmark of these platforms is that they can assemble and display up to 72 monomeric nanobody units if properly engineered. Thought-provokingly, since the SARS-CoV-2 viral architecture contains 24 ± 9 spike trimer units [91], this multi-affinity nanobody approach may uniquely crosslink several viruses into a defective state. In this case, protein cages such as ferritin (24-mer) [123], dihydrolipoil acetyltransferase [124], and Lumazine synthase (60-mer) [125] could be exploited. Notably, these scaffolds have previously been used to display several proteins [126–129].

In the context of coronavirus disease, Rujas et al. [130] genetically fused an already reported VHH-72 to the N-terminal light chain of human apoferritin protomer to generate an ultrapotent SARS-CoV-2 neutralizer. Herein, the modular unit successfully assembled 24 copies of VHH-72 into homogenous spherical particles with high avidity towards SARS-CoV-2-S. Remarkably, the 24-mer VHH-72 particle showed approximately 10,000-fold blocking potency in comparison to the IgG counterparts. In terms of VLPs, many useful scaffolds such as VP1, MS2, HPV, HbsAg and AP205 are available to display more than 60 copies of nanobody for SARS-CoV-2 neutralization applications. However, VLP-based super-scaffolds (72-mer) have not been applied yet in light of nanobody presentation. Nevertheless, they find applications in diverse antigen presentation as reviewed already reviewed [131]. Fig. 5 summarizes the protein engineering
| Nanobody Name     | Source and method | Virus Type | Binding Mechanism of neutralization/inhibition | Protective efficacy | Ref |
|-------------------|-------------------|------------|-----------------------------------------------|---------------------|-----|
| Vag2              | Immune library + phage display, IgG Fc fusion | SARS-CoV-1 | Recognize epitope residues (Trp100, Tyr356/494, Cys366, Phe391) on spike RBD | Neutralized SARS-CoV-1 and −2 pseudoviruses and live SARS-CoV-1, −2 and variant SARS-CoV-2 | N/A |
| Vag3              | Immune library + phage display, IgG Fc fusion | SARS-CoV-2 | Recognize epitope residues (121 – S375) via anti-parallel β-strand hydrogen bond | Neutralized SARS-CoV-2 pseudoviruses and live SARS-CoV-2 virus | N/A |
| Ty1               | Immune library + phage display, IgG Fc fusion | SARS-CoV-2 | Recognize epitope residues (Tyr470, V483-E484, Y449, F490, Q493) | Neutralized SARS-CoV-2 pseudoviruses and live SARS-CoV-2 virus | N/A |
| Ty2               | Immune library + phage display, IgG Fc fusion | SARS-CoV-2 | Recognize epitope residues (381 – S375) via antiparallel β-strand hydrogen bond | Neutralized SARS-CoV-2 pseudoviruses and live SARS-CoV-2 virus | N/A |
| Ty1-Fc            | Immune library + phage display, IgG Fc fusion | SARS-CoV-2 | Recognize epitope residues (Y109, E484, F486, Q493, N501, K417, R403) | Neutralized SARS-CoV-2 pseudoviruses and live SARS-CoV-2 virus | N/A |
| Ty2-3 Fc          | Immune library + phage display, IgG Fc fusion | SARS-CoV-2 | Recognize epitope residues (Y109, E484, Q493, N501, K417, R403) | Neutralized SARS-CoV-2 pseudoviruses and live SARS-CoV-2 virus | N/A |
| Ty1-3 Fc          | Immune library + phage display, IgG Fc fusion | SARS-CoV-2 | Recognize epitope residues (Y109, E484, Q493, N501, K417, R403) | Neutralized SARS-CoV-2 pseudoviruses and live SARS-CoV-2 virus | N/A |
| Ty2-3 Fc          | Immune library + phage display, IgG Fc fusion | SARS-CoV-2 | Recognize epitope residues (Y109, E484, Q493, N501, K417, R403) | Neutralized SARS-CoV-2 pseudoviruses and live SARS-CoV-2 virus | N/A |
| Ty1-3 Fc          | Immune library + phage display, IgG Fc fusion | SARS-CoV-2 | Recognize epitope residues (Y109, E484, Q493, N501, K417, R403) | Neutralized SARS-CoV-2 pseudoviruses and live SARS-CoV-2 virus | N/A |
| Ty2-3 Fc          | Immune library + phage display, IgG Fc fusion | SARS-CoV-2 | Recognize epitope residues (Y109, E484, Q493, N501, K417, R403) | Neutralized SARS-CoV-2 pseudoviruses and live SARS-CoV-2 virus | N/A |
| Ty1-3 Fc          | Immune library + phage display, IgG Fc fusion | SARS-CoV-2 | Recognize epitope residues (Y109, E484, Q493, N501, K417, R403) | Neutralized SARS-CoV-2 pseudoviruses and live SARS-CoV-2 virus | N/A |
| Ty2-3 Fc          | Immune library + phage display, IgG Fc fusion | SARS-CoV-2 | Recognize epitope residues (Y109, E484, Q493, N501, K417, R403) | Neutralized SARS-CoV-2 pseudoviruses and live SARS-CoV-2 virus | N/A |
| Ty1-3 Fc          | Immune library + phage display, IgG Fc fusion | SARS-CoV-2 | Recognize epitope residues (Y109, E484, Q493, N501, K417, R403) | Neutralized SARS-CoV-2 pseudoviruses and live SARS-CoV-2 virus | N/A |
| Ty2-3 Fc          | Immune library + phage display, IgG Fc fusion | SARS-CoV-2 | Recognize epitope residues (Y109, E484, Q493, N501, K417, R403) | Neutralized SARS-CoV-2 pseudoviruses and live SARS-CoV-2 virus | N/A |
Table 1 continued

| Nanobody Name | Source and method | Virus type | Binding affinity (Kd) | Neutralizing activity (IC<sub>50</sub>) | Protective efficacy | Ref |
|----------------|-------------------|------------|-----------------------|----------------------------------------|--------------------|-----|
| **Neutralizing** | **Mechanism of neutralization/inhibition** | **Protective efficacy** | **Ref** |
| **VH IgG Fc fusion** | 0.12 nM | 4.0 nM | Neutralize SARS-CoV-2 \(N/A [60]\) | | |
| **Multivalent** | 84/200 pM | 0.7–1.32 nM | | Biparatopic/Bivalent library | Escape epitopes on spike RBD in different orientation; Nanobodies trigger activation of the fusion machinery; \(N/A [150]\) | |
| **Trivalent** | 30 nM | 9.3 nM | Block ACE2–RBD interaction; Neutralize pseudotyped and authentic SARS-CoV-2 virus | Trivalent | Block ACE2–RBD interaction; Neutralize pseudotyped and authentic SARS-CoV-2 virus | |
| **VH-V, U and E bind and recognize distinct ACE2 binding epitopes on spike RBD in different orientation** | 1.86–22 nM | 60 nM | \(N/A [60]\) | | |
| **Biparatopic/Bivalent library** | 0.12 nM | 170 nM | Neutralized pseudotyped SARS-CoV-2 \(<1 \text{ pM (detection limit)}\) | | |
| **Biaryl-amidated and antibody SARS-CoV-2 virus** | 0.12 nM | 170 nM | | | |
| **SARS-CoV-2** | 0.12 nM | 36.8 nM | Neutralized pseudotyped SARS-CoV-2 | | |

Herein, advancements in particulate nanotechnology in areas such as inhalable [135–137] and injectable [138,139] nanomaterials show tremendous promises for applications in medicine. These materials include, but are not limited to, liposomes, dendrimers, polymers, fullerences, nanoribbons, carbon nanotubes and dots (Fig. 6A). Although these nanomaterials possess excellent bioavailability and pharmacokinetics of medicinal relevance [140], yet they remain to be fully utilized. Also, the surface area of these nanomaterials is highly available for implanting a plethora of ligands at high densities for avidity-inspired drug delivery purposes.

Focusing on inhalable nanoparticles by virtue of their potential in curbing lung-associated diseases, many incredible chemistries could be applied on these nanoparticles in tandem with anti-SARS-CoV-1 and –2 nanobodies towards achieving avidity responses. In fact, the past two decades have seen several efforts towards achieving orthogonal, site-specific multivalent molecules through chemical exploitation of inherent reactive functional groups [141–145], genetic code expansion [146–149] and enzymatic approaches [150–152]. There is, therefore, no right time but now to consider these options for improving the avidity of viral blocking molecules such as nanobodies. In the case of avidity-inspired nanobodies, the chemical functionalization approach will be preferable for carrier nanoparticle modification, whereas the genetic code expansion and enzymatic approaches would favour protein modification due to the mild reaction requirements. In the genetic synthesis approach, aminoacyl tRNA synthetases (aaRS) are used to recognize and replace specific codons (e.g., amber UAG) with an unnatural amino acid that bears the required orthogonal reactive handle [153]. Enzymatic approaches such as proximity-dependent biotinylation [154–157] and sortase A (Srt A) transpeptidation [158–161] facilely append handles necessary for multimerizing nanobodies on nanocarriers. For instance, in proximity-dependent biotinylation (Fig. 6B), enzymes such as biotin ligase (BirA) attach biotin molecules via nucleophilic interaction onto Avi tag (GLNDIFEAQKIEWHE) bearing proteins using Mg<sup>2+</sup> and ATP as cofactors [162]. The biotinylated protein can then be multimerized on nanoparticle carriers exploiting the strong binding affinity between biotin and streptavidin (K<sub>d</sub> = 4 × 10<sup>-14</sup> M; Fig. 6C) [163,164]. Herein, the approach has been used to produce tetrameric molecules for cancer treatment [165,166]. In Srt A transpeptidation (Fig. 5D), the enzyme recognizes the C-terminal peptide motif (LPXTG) on target molecules, cleaving between threonine (T) and glycine (G), and ligates available molecules bearing N-terminal glycine repeat. The “X” is preferably aspartic acid (D), glutamic acid (E), alanine (A), asparagine (N), glutamine (Q) or lysine (K). The transpeptidation mechanism is mostly Ca<sup>2+</sup> dependent, but there is a Ca<sup>2+</sup> independent variant available [167]. In view of this, several applications associated with protein multi-functionalization [161], protein cyclization [168], protein lipidation [169], and cell-surface labelling [170,171] have been attempted. Modifications such as C- to N-terminal [172,173], N- to C-terminal [174,175], and unnatural C- to C- and N-to N-terminal [176] are available. The method could be complemented with click chemistry to load functional nanobodies onto nanoparticles to obtain avidity-inspired therapeutics, as depicted in Fig. 6E. These products can easily be formulated and delivered via the nasal route at low dosages for coronavirus and respiratory infections. In line with these approaches, Moliner-morro et al. [177] has reported bivalent (Ty1-Ty1 and Ty1-PEG-Ty1) and 4-arm polylethylene glycol (PEG) tetrameric construct using combined Srt A transpeptidation and strain promoted azide-alkyne click chemistry. Herein, the bivalent formats
yielded a similar potency as Ty1-Fc fusion, whereas the tetrameric Ty1 construct dramatically neutralized SARS-CoV-2 at IC\textsubscript{50} = ~13 pM. The group has further reported that their bispecific nanobody induces spike trimer dimerization [95]. Having these toolsets available, it is important to note that bioconjugation approaches for medical applications must be orthogonal and site-specific, yielding safe and quantitative products. Therefore, safety verifications of the final product are mandated.

Avidity-inspired nanobody therapeutics: outlook

Recently, traditional antibody therapeutics for viral disease treatment has shown the potential to intensify viral infections or cause detrimental immunopathology via a phenomenon known as antibody-dependent enhancement (ADE). Simply put, ADE results from an antibody-Fc receptor (FcR) complex-mediated virus uptake into phagocytic cells, which results in heightened inflammation and tissue injury (reviewed in [178–180]). While ADE is improbable for nanobody therapeutics bearing no Fc domains, multivalent nanobodies fused with immunoglobulin Fc may exhibit some potential danger. However, there is no direct evidence of COVID-19 or SARS-related ADE reported for nanobody-Fc fusion to date, partly because of inadequate knowledge of ADE and assessment techniques. Since the ADE effect is generally overlooked, we suggest that a careful selection, engineering and optimization of immunoglobulin Fc domains that offer improved potency and safer routes be considered. For instance, Yamin et al. [181] and Pinto et al. [182] have exceptionally demonstrated approaches to circumvent detrimental immunopathology, which may prove helpful for avidity-inspired therapeutics.

Also, with the potential of nanobodies to prevent viral escape with no autoimmune responses, the future of avidity-inspired nanobody therapeutics remains oceanic. For instance, we foresee an overflow of exploitation of de novo protein design strategies [183–186] that have the potential to generate complex non-immunogenic protein scaffolds for use in avidifying nanobodies in no distant future. A case in point is reported by Divine et al. [187], where antibodies were computationally clustered within a protein super-structure for SARS-CoV-2 neutralization. Many more in line with this is anticipated.

Conclusion

Nanobody technology remains a versatile therapeutic approach of high potential in the emergence of coronavirus disease and associated variants of concern. Considering the trajectory of coronavirus, with different variants appearing quarterly, the focus now is on approaches to easily multimerized these potent inhibitors into high-avidity therapeutics. Many highlighted approaches concerning protein engineering and nanoparticle chemistry are available and ready to be explored towards advanced innovations in treatment technologies. With uncompromised safety implemented, the product can be formulated and delivered via the nasal route at low dosages to treat coronavirus and other respiratory infections.

CRediT authorship contribution statement

Eugene M. Obeng: Conceptualization, Writing – original draft, Writing – review & editing, Visualization. Christian K.O. Dzuvor: Writing – original draft, Writing – review & editing. Michael K. Danquah: Writing – review & editing, Supervision.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgement

EMO and CKOD acknowledge Monash Graduate Scholarship for their PhD studies. The figures were drawn and assembled with
Conflict of interest

The authors declare no conflict of interest.

References

[1] Y. Dong, T. Dai, Y. Wei, L. Zhang, M. Zheng, F. Zhou, A systematic review of SARS-CoV-2 vaccine candidates: Signal Transduct. Target. Ther. 5 (2020) 237, https://doi.org/10.1038/s41392-020-00352-y

[2] Y. Der Li, W.Y. Chi, J.H. Su, L. Ferrall, C.F. Hung, T.C. Wu, Coronavirus vaccine development: from SARS and MERS to COVID-19, J. Biomed. Sci. 27 (2020) 1–23, https://doi.org/10.1186/s12929-020-00905-2

[3] G.A. Poland, I.G. Ovsyannikova, R.B. Kennedy, SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates, Lancet 396 (2020) 1595–1606, https://doi.org/10.1016/S0140-6736(20)32137-1

[4] P.C. Taylor, A.C. Adams, M.M. Hufford, I. de la Torre, K. Winthrop, R.L. Gottlieb, Neutralizing monoclonal antibodies for treatment of COVID-19, Nat. Rev. Immunol. 21 (2021) 382–393, https://doi.org/10.1038/s41567-021-00947-x

[5] A. Idris, A. Davis, A. Supramaniam, D. Acharya, G. Kelly, A. Davis, A. Supramaniam, D. Acharya, G. Kelly, Y. Taayar, N. West, A. Idris, A. Davis, A. Supramaniam, D. Acharya, G. Kelly, Y. Taayar, N. West, Y. Chen, Q. Liu, D. Guo, Emerging coronaviruses: genome structure, replication and pathobiology, Biochim. Biophys. Acta - Gen. Subj. 1863 (2021) 1–9, https://doi.org/10.1016/j.bbabio.2020.110977

[6] K. Duan, B. Liu, C. Li, H. Zhang, T. Yu, J. Qu, M. Zhou, L. Chen, S. Meng, Y. Hu, C. Peng, M. Yuan, J. Huang, Z. Wang, J. Yu, X. Gao, D. Wang, X. Yu, L. Li, J. Zhang, X. Wu, B. Li, L. Yu, X. Chen, Y. Peng, Y. Hu, L. Lin, X. Liu, S. Huang, Z. Liao, Z. Sun, Z. Wang, B. Xie, G. Gong, W. Zhang, X. Zheng, Y. Liu, H. Yang, D. Zhou, D. Yu, J. Hou, Z. Shi, S. Chen, Z. Chen, X. Zhang, X. Yang, Effectiveness of convalescent plasma therapy in severe COVID-19 patients, Proc. Natl. Acad. Sci. 117 (2020) 9490–9496, https://doi.org/10.1073/pnas.2014961117

[7] J.K. Millet, G.R. Whitaker, Host cell proteases: critical determinants of coronavirus tropism and pathogenesis, Virus Res 202 (2015) 120–134, https://doi.org/10.1016/j.virres.2014.11.021

[8] L. Du, Y. He, Y. Zhou, S. Liu, B.J. Zheng, S. Jiang, The spike protein of SARS-CoV-2 is essential for infection of human lung cells, Mol. Immunol. 21 (2021) 10879–10884, https://doi.org/10.1016/j.molimm.2020.102866

[9] L. Zhang, Y. Wang, Z. Zhang, K. Deng, Z. Xia, Q. Gong, W. Zhang, X. Zheng, L. Zhang, X. Wang, S. Huang, Z. Zhou, S. Jiang, T. Ying, Identification of human single-domain antibodies against SARS-CoV-2 spike protein via phage display, Sci. Rep. 10 (2020) 20041, https://doi.org/10.1038/s41598-020-73550-9

[10] Y. Dong, T. Dai, Y. Wei, L. Zhang, M. Zheng, F. Zhou, A systematic review of SARS-CoV-2 vaccine candidates: Signal Transduct. Target. Ther. 5 (2020) 237, https://doi.org/10.1038/s41392-020-00352-y
P. Kunz, K. Zinner, N. Mücke, T. Bartoschik, S. Muyldermans, J.D. Hoheisel, The V. Joosten, R.J. Gouka, C.A.M.J.J. Van Den Hondel, C.T. Verrips, B.C. Lokman, J. Govaert, M. Pellis, N. Deschacht, C. Vincke, K. Conrath, S. Muyldermans, S. Muyldermans, Single domain camel antibodies: current status, Rev. Mol. Technol. 30 (2002) 273–278, https://doi.org/10.1016/S0141-0229(01)00497-5.

V. Joosten, R.J. Gaul, J. Roost, C.T. Verrips, Specific production rate of VH antibody fragments by Saccharomyces cerevisiae correlated with growth rate, independent of nutrient limitation, J. Biotechnol. 118 (2005) 270–277, https://doi.org/10.1016/j.jbiotec.2005.07.016.

V.E. Thomsen, A.M. Saunders, L. Sierkstra, C.T. Verrips, Large-scale production of VH antibody fragments by Saccharomyces cerevisiae, Enzym. Microb. Technol. 30 (2002) 273–278, https://doi.org/10.1016/S0141-0229(01)00497-5.

T. van de Laar, C. Visser, M. Holster, C.G. López, D. Kreuning, L. Sierkstra, N. van der Beek, T. Reehorst, J.A. Melero, K. Zarschler, S. Witecy, F. Kapplusch, C. Förster, H. Stephan, High-yield production of functional soluble single-domain antibodies in the cytoplasm of Escherichia coli, Microb. Cell Fact. 12 (2013) 97, https://doi.org/10.1186/1475-2859-12-97.

V. Joosten, R.J. Gaul, C.A.M.J.J. Van Den Hondel, C.T. Verrips, B.C. Lokman, Expression and production of llama variable heavy-chain antibody fragments (VHs) by Aspergillus awamori, Appl. Microbiol. Biotechnol. 66 (2005) 384–392, https://doi.org/10.1007/s00253-005-2575-4.

J. Hau, A. Le Bas, R.R. Huza, H.M.E. Duyvestyn, H. Mikolajek, T. Malinauskas, P.C. Friddy, Y. Li, S. Keegan, M.K. Thompson, I. Nudelman, J.F. Scheid, M. Oeffinger, Y.E. Thomassen, W. Meier, L. Sierkstra, C.T. Verrips, Large-scale production of Escherichia coli, Microb. Cell Fact. 12 (2013) 97, https://doi.org/10.1186/1475-2859-12-97.

P.A. Koenig, H. Das, H. Liu, B.M. Kümmerer, F.N. Gohr, L.-M. Jenster, L.D.J. Schifflers, Y.M. Tesfamariam, M. Uchima, J.D. Wuertz, K. Gattermann, N. Ruetalo, M.H. Christensen, C. Fandrey, S. Normann, J.M.P. Todtmann, S. Fehn, L. Hanko, H. Hulsen, M. Yuan, X. Luo, M. C. Schindler, I.A. Wilson, M. Geyer, K.U. Ludwig, B.M. Hallberg, N.C. Wu, F.J. Schmidt, Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape, Science 371 (2021) eabe2230, https://doi.org/10.1126/science.abe2230.

L. Hanke, L. Vidakovich Perez, D.J. Sheward, H. Das, T. Schulte, A. Moliner-Morro, M. Corcoran, A. Achour, G.B. Karlsson Hedebrant, H.M. Hallberg, B. Murrell, G.M. McNelmes, An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction on cells. Nat. Commun. 11 (2020) 4420, https://doi.org/10.1038/s41467-020-18174-5.

P. Kroy, F. Neumayer, N. Mücke, W. Dold, L. Sierkstra, C.T. Verrips, D. Gottschalk, P. Kunz, K. Zinner, J. Govaert, M. Pellis, N. Deschacht, C. Vincke, K. Conrath, S. Muyldermans, S. Muyldermans, Single domain camel antibodies: current status, Rev. Mol. Technol. 30 (2002) 273–278, https://doi.org/10.1016/S0141-0229(01)00497-5.

P. Kuz, K. Zinner, N. Mücke, T. Bartoschik, S. Muyldermans, J.D. Hoheisel, The structural basis of nanobody unfolding reversibility and thermostability. Science 368 (2018) 1–10, https://doi.org/10.1126/science.aao9096.

P. Kunz, K. Zinner, N. Mücke, T. Bartoschik, S. Muyldermans, J.D. Hoheisel, The structural basis of nanobody unfolding reversibility and thermostability. Science 368 (2018) 1–10, https://doi.org/10.1126/science.aao9096.

P. Kunz, K. Zinner, N. Mücke, T. Bartoschik, S. Muyldermans, J.D. Hoheisel, The structural basis of nanobody unfolding reversibility and thermostability. Science 368 (2018) 1–10, https://doi.org/10.1126/science.aao9096.
S.A. Koesteny, M.S. Cole, J.V. Tso, Formation of a bispecific antibody by the use of leucine zippers, J. Immunol. 148 (1992) 1547–1553.

G. Wu, B. Wang, W. Xu, Y. Ren, Y. Zhang, Z. Xiao, Y. Li, M. Zhang, X. Cai, J. Song, X. Xie, Y. Liu, L. Li, B. Zhang, J.-y. Li, A. Chiang, ACE2 binds viral spike protein and locks it in "Three-up" configuration to potently inhibit SARS-CoV-2 infection, Cell Res. 31 (2021) 98–100. https://doi.org/10.1038/s41422-020-00438-w

M. Fletcher, A.J. Boyle, M. Brunning, G.J. Bartlett, T.L. Vincent, N.R. Zaccari, C.T. Armstrong, E.H.C. Bromley, P.J. Booth, R.L. Brady, A basis set of de novo coiled-coil peptide oligomers for rational protein design and synthetic biology, ACS Synth. Biol. 1 (2012) 240–250.

P. Forcier, C. Chang, F. Muhlcner, R. Wodawer, A. Plückthun, Kinetic stability and crystal structure of the viral capid protein SH, J. Mol. Biol. 344 (2004) 179–193.

C. Fan, C. Huang, W. Chiu, C. Lai, G. Liu, H. Li, M. Chou, Production of multivalent protein binders using a self-trimerizing collagen-like peptide scaffold, PNAS 12 (2008) 3795–3804.
